| Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response P Jiang, S Gu, D Pan, J Fu, A Sahu, X Hu, Z Li, N Traugh, X Bu, B Li, J Liu, ... Nature medicine 24 (10), 1550-1558, 2018 | 3827 | 2018 |
| TIMER2. 0 for analysis of tumor-infiltrating immune cells T Li, J Fu, Z Zeng, D Cohen, J Li, Q Chen, B Li, XS Liu Nucleic acids research 48 (W1), W509-W514, 2020 | 3786 | 2020 |
| Large-scale public data reuse to model immunotherapy response and resistance J Fu, K Li, W Zhang, C Wan, J Zhang, P Jiang, XS Liu Genome medicine 12 (1), 1-8, 2020 | 779 | 2020 |
| Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade SS Gu, W Zhang, X Wang, P Jiang, N Traugh, Z Li, C Meyer, B Stewig, ... Cancer discovery 11 (6), 1524-1541, 2021 | 163 | 2021 |
| Landscape of B cell immunity and related immune evasion in human cancers X Hu, J Zhang, J Wang, J Fu, T Li, X Zheng, B Wang, S Gu, P Jiang, J Fan, ... Nature genetics 51 (3), 560-567, 2019 | 151 | 2019 |
| In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target X Wang, C Tokheim, SS Gu, B Wang, Q Tang, Y Li, N Traugh, Z Zeng, ... Cell 184 (21), 5357-5374. e22, 2021 | 131 | 2021 |
| TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response Z Zeng, CJ Wong, L Yang, N Ouardaoui, D Li, W Zhang, S Gu, Y Zhang, ... Nucleic acids research 50 (D1), D1391-D1397, 2022 | 79 | 2022 |
| Immune receptor repertoires in pediatric and adult acute myeloid leukemia J Zhang, X Hu, J Wang, AD Sahu, D Cohen, L Song, Z Ouyang, J Fan, ... Genome medicine 11, 1-11, 2019 | 50 | 2019 |
| Inhibition of MAN2A1 enhances the immune response to anti–PD-L1 in human tumors S Shi, S Gu, T Han, W Zhang, L Huang, Z Li, D Pan, J Fu, J Ge, M Brown, ... Clinical Cancer Research 26 (22), 5990-6002, 2020 | 44 | 2020 |
| Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer G Oliveira, AM Egloff, AB Afeyan, JO Wolff, Z Zeng, RD Chernock, L Zhou, ... Science immunology 8 (87), eadf4968, 2023 | 43 | 2023 |
| Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation L Penter, Y Zhang, A Savell, T Huang, N Cieri, EM Thrash, S Kim-Schulze, ... Blood, The Journal of the American Society of Hematology 137 (23), 3212-3217, 2021 | 41 | 2021 |
| Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders L Zhou, Z Zeng, AM Egloff, F Zhang, F Guo, KM Campbell, P Du, J Fu, ... Journal for immunotherapy of cancer 10 (1), e004034, 2022 | 34 | 2022 |
| Discovery of targets for immune–metabolic antitumor drugs identifies estrogen-related receptor alpha A Sahu, X Wang, P Munson, JPG Klomp, X Wang, SS Gu, Y Han, G Qian, ... Cancer discovery 13 (3), 672-701, 2023 | 19 | 2023 |
| Clonal tracing reveals diverse patterns of response to immune checkpoint blockade SS Gu, X Wang, X Hu, P Jiang, Z Li, N Traugh, X Bu, Q Tang, C Wang, ... Genome biology 21, 1-28, 2020 | 19 | 2020 |
| Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA L Yang, J Wang, J Altreuter, A Jhaveri, CJ Wong, L Song, J Fu, L Taing, ... Nature Protocols 18 (8), 2404-2414, 2023 | 14 | 2023 |
| A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer M Mason, Ó Lapuente-Santana, AS Halkola, W Wang, R Mall, X Xiao, ... Journal of translational medicine 22 (1), 190, 2024 | 9 | 2024 |
| Cross-site concordance evaluation of tumor DNA and RNA sequencing platforms for the CIMAC-CIDC network Z Zeng, J Fu, C Cibulskis, A Jhaveri, C Gumbs, B Das, ... Clinical Cancer Research 27 (18), 5049-5061, 2021 | 8 | 2021 |
| Cancer cell resistance to IFNγ can occur via enhanced double-strand break repair pathway activity T Han, X Wang, S Shi, W Zhang, J Wang, Q Wu, Z Li, J Fu, R Zheng, ... Cancer Immunology Research 11 (3), 381-398, 2023 | 6 | 2023 |
| 503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma A Afeyan, G Oliveira, AM Egloff, Z Zeng, R Chernock, L Zhou, C Messier, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer AC Garrido-Castro, N Graham, K Bi, J Park, J Fu, T Keenan, ... Cancer Research 82 (4_Supplement), P2-14-18-P2-14-18, 2022 | 2 | 2022 |
Xiaole Shirley LiuCEO, GV20 TherapeuticsVerificeret mail på ds.dfci.harvard.edu